BSA nanoparticle loaded atorvastatin calcium--a new facet for an old drug.
BACKGROUND
Currently, the discovery of effective chemotherapeutic agents poses a major challenge to the field of cancer biology. The present study focuses on enhancing the therapeutic and anti cancer properties of atorvastatin calcium loaded BSA (ATV-BSA) nanoparticles in vitro.


RESULTS
BSA-ATV nanoparticles were prepared using desolvation technique. The process parameters were optimized based on the amount of desolvating agent, stabilization conditions as well as the concentration of the cross linker. The anti cancer properties of the protein coated ATV nanoparticles were tested on MiaPaCa-2 cell lines. In vitro release behavior of the drug from the carrier suggests that about 85% of the drug gets released after 72 hrs. Our studies show that ATV-BSA nanoparticles showed specific targeting and enhanced cytotoxicity to MiaPaCa-2 cells when compared to the bare ATV.


CONCLUSIONS
We hereby propose that the possible mechanism of cellular uptake of albumin bound ATV could be through caveolin mediated endocytosis. Hence our studies open up new facet for an existing cholesterol drug as a potent anti-cancer agent.
Center for Nanotechnology and Advanced Biomaterials (CeNTAB), School of Chemical and Biotechnology, SASTRA University, Tirumalaisamudram, Thanjavur, India.
S
S
Sripriyalakshmi
Center for Nanotechnology and Advanced Biomaterials (CeNTAB), School of Chemical and Biotechnology, SASTRA University, Tirumalaisamudram, Thanjavur, India.
C H
CH
Anjali
Medical Biotechnology Division, School of Biosciences and Technology, VIT University, Vellore, India.
Priya Doss C
PD
George
Medical Biotechnology Division, School of Biosciences and Technology, VIT University, Vellore, India.
B
B
Rajith
Center for Nanotechnology and Advanced Biomaterials (CeNTAB), School of Chemical and Biotechnology, SASTRA University, Tirumalaisamudram, Thanjavur, India.
Aswathy
A
Ravindran
D000328:Adult; D000818:Animals; D000924:Anticholesteremic Agents / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics*; D000970:Antineoplastic Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D000069059:Atorvastatin; D002417:Cattle; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D006461:Hemolysis / Q000187:drug effects; D006538:Heptanoic Acids / Q000737:chemistry / Q000493:pharmacokinetics* / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D018613:Microscopy, Confocal; D008855:Microscopy, Electron, Scanning; D062105:Molecular Docking Simulation; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D010190:Pancreatic Neoplasms / Q000378:metabolism / Q000473:pathology; D011758:Pyrroles / Q000737:chemistry / Q000493:pharmacokinetics* / Q000494:pharmacology; D017382:Reactive Oxygen Species / Q000378:metabolism; D012710:Serum Albumin, Bovine / Q000737:chemistry*; D013050:Spectrometry, Fluorescence; D017550:Spectroscopy, Fourier Transform Infrared; D013997:Time Factors
D000924:Anticholesteremic Agents; D000970:Antineoplastic Agents; D006538:Heptanoic Acids; D011758:Pyrroles; D017382:Reactive Oxygen Species; D012710:Serum Albumin, Bovine; D000069059:Atorvastatin